Because SOD2 is known to be reduced in PH patients (Bowers et al., 2004; Archer et al., 2010), and SOD2 siRNA creates a PAH phenotype in vascular SMC (Archer et al., 2010), this suggests that ACE2 treatment could fill a necessary void in PH treatment by decreasing vascular remodeling. This evidence concerns the gene SOD2 and pulmonary arterial hypertension.